Objective. Arsenic trioxide (ATO) has been effectively used for the treatment of hematological malignancies and some solid tumors, while ATO effects were not tested clinically in epithelial ovarian cancer (EOC). Methods. Patients with primary or secondary platinum-resistant EOC were enrolled from October 2015 to December 2019. Patients were mainly treated with ATO-based combined sequential chemotherapy as follows: Regimen 1 (ATO combined taxanes weekly therapy); Regimen 2 (ATO + taxanes + 5-fluorouracil + adriamycin ± bevacizumab sequential chemotherapy), for 5 patients platinum-free interval >12 months, added oxaliplatin). Prespecified end points in this cohort included confirmed best overall response rate (ORR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and safety. Results. A total of 33 patients were enrolled in this study. After a median follow-up time of 22.1 months (range 5.5–42.9 months), ORR was 42% and DCR was 85%. The overall PFS was 9.5 months (range 1–38.4 months). The main side effect was myelosuppression. Conclusions. ATO-based sequential combined chemotherapy is effective for primary and recurrent drug-resistant EOC patients in clinical phase II trials. The associated side effects could be controlled, while further study is needed.

Background: The objective of this study was to characterize the expression features base on three genes, including DUSP1, BUB1 and MCM7, and investigate their clinical significance in Chinese cohort with endometrial carcinoma. Materials and methods. Immunohistochemistry (IHC) was performed for assessing the expression of DUSP1, BUB1, and MCM7 in these patients. The associations between the expressions of three genes and the clinicopathological features were analyzed. The risk model was finally validated in TCGA cohort. Results: The expressions of DUSP1, BUB1, and MCM7 were associated with clinicopathological features (P＜0.05 for all). Patients with high expression level of DUSP1 and low expression level of BUB1 and MCM7 had better prognosis. The construction combining these three genes is an independent risk factor and had a high accuracy in predicting overall survival (OS, AUC=0.923) and disease-free survival (DFS, AUC=0.963). The three-gene risk signature was validated in TCGA-EC cohort, and the results showed a great precision for predicting OS and DFS (both AUC>0.7) in an external group. Conclusions: Our study revealed a three-gene prognostic signature, including DUSP1, BUB1, and MCM7, and its related nomogram could guide personalized strategy, providing a basis for the molecular analysis in EC, thereby improving their OS and DFS.

No abstract